On Tuesday, Prime Medicine Inc (NASDAQ: PRME) was -6.60% drop from the session before settling in for the closing price of $3.03. A 52-week range for PRME has been $2.56 – $9.77.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -25.00% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 26.60%. With a float of $50.89 million, this company’s outstanding shares have now reached $131.16 million.
In an organization with 234 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 98.47%, operating margin of -586.63%, and the pretax margin is -568.39%.
Prime Medicine Inc (PRME) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Prime Medicine Inc stocks. The insider ownership of Prime Medicine Inc is 61.20%, while institutional ownership is 36.18%. The most recent insider transaction that took place on Feb 15 ’24, was worth 20,000,000. In this transaction Director of this company bought 3,200,000 shares at a rate of $6.25, taking the stock ownership to the 3,200,000 shares. Before that another transaction happened on Feb 15 ’24, when Company’s 10% Owner bought 3,200,000 for $6.25, making the entire transaction worth $20,000,000. This insider now owns 3,200,000 shares in total.
Prime Medicine Inc (PRME) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 26.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.17% during the next five years compared to -193.88% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
You can see what Prime Medicine Inc (PRME) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 463.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.01, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.22 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Let’s dig in a bit further. During the last 5-days, its volume was 0.92 million. That was better than the volume of 0.84 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 47.71%. Additionally, its Average True Range was 0.25.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 10.98%, which indicates a significant decrease from 23.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.17% in the past 14 days, which was lower than the 81.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.08, while its 200-day Moving Average is $4.53. However, in the short run, Prime Medicine Inc’s stock first resistance to watch stands at $2.98. Second resistance stands at $3.13. The third major resistance level sits at $3.20. If the price goes on to break the first support level at $2.75, it is likely to go to the next support level at $2.68. Assuming the price breaks the second support level, the third support level stands at $2.53.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
There are 131,161K outstanding shares of the company, which has a market capitalization of 371.19 million. As of now, sales total 0 K while income totals -198,130 K. Its latest quarter income was 210 K while its last quarter net income were -52,520 K.
